富馬酸喹硫平片聯(lián)合阿立哌唑片治療精神分裂癥的臨床研究
發(fā)布時(shí)間：2019-01-14 14:16
【摘要】：目的觀察富馬酸喹硫平片聯(lián)合阿立哌唑片治療精神分裂癥的臨床療效及安全性。方法將70例精神分裂癥患者隨機(jī)分為對照組35例和試驗(yàn)組35例。對照組予以阿立哌唑,初始劑量5 mg·d~(-1),bid,口服;根據(jù)病情1周內(nèi)逐漸增加至20~30 mg·d~(-1),bid。試驗(yàn)組予以阿立哌唑5~10 mg·d~(-1),bid,口服+富馬酸喹硫平,最初劑量為100 mg·d~(-1),bid,口服;根據(jù)病情逐漸增加,在1周內(nèi)將富馬酸喹硫平的劑量調(diào)整為400~600 mg·d~(-1),bid;治療1個(gè)月后,根據(jù)患者具體病情將富馬酸喹硫平的劑量增加至800 mg·d~(-1),bid。2組患者均治療2個(gè)月。比較2組患者的臨床療效、簡明精神疾病評定量表(BPRS)評分、匹茲堡睡眠質(zhì)量指數(shù)(PSQI)、陽性與與陰性癥狀量表(PANSS)評分,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對照組的總有效率分別為88.57%(31/35例)和85.71%(30/35例),差異無統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組與對照組的BPRS總分分別為(34.57±2.67),(41.95±1.64)分;PSQI總分分別為(6.49±0.19),(13.05±0.97)分,差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。治療后,試驗(yàn)組與對照組的陽性癥狀評分分別為(15.66±1.21),(15.52±1.32)分;陰性癥狀分別為(14.84±1.63),(15.13±1.10)分;病理癥狀分別為(31.37±2.19),(31.32±2.19)分;PANSS總分分別為(66.56±2.34),(66.10±2.37)分,差異均無統(tǒng)計(jì)學(xué)意義(均P0.05)。試驗(yàn)組發(fā)生的藥物不良反應(yīng)主要有惡心嘔吐、心動過速、靜坐不能、震顫;對照組發(fā)生的藥物不良反應(yīng)主要有失眠癥狀、心動過速、肌強(qiáng)直、靜坐不能、流涎。試驗(yàn)組和對照組的藥物不良反應(yīng)發(fā)生率分別為17.14%和45.71%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論富馬酸喹硫平片聯(lián)合阿立哌唑片與單用阿立哌唑片治療精神分裂癥的臨床療效相當(dāng),但前者可顯著改善患者的病情和睡眠質(zhì)量,且安全性較高。
[Abstract]:Objective to observe the efficacy and safety of quintiapine fumarate tablets combined with aripiprazole tablets in the treatment of schizophrenia. Methods 70 patients with schizophrenia were randomly divided into control group (n = 35) and experimental group (n = 35). The control group was given aripiprazole at an initial dose of 5 mg D1), bid, and gradually increased to 2030 mg D1), bid. within 1 week according to the condition of the disease. In the experimental group, aripiprazole was given orally for 10 mg D1), bid, and the initial dose was 100 mg D1), bid,. According to the gradual increase of the disease, the dose of quinolipine fumarate was adjusted to 400 ~ (-1) mg / d ~ (-1), bid; within one week. After one month of treatment, the dosage of quetiapine fumarate was increased to 800 mg D1 according to the specific condition of the patients. The patients in the bid.2 group were treated for 2 months. The clinical efficacy, (BPRS) score of brief psychiatric rating scale, (PANSS) score of Pittsburgh Sleep quality Index (PSQI),) positive and negative symptom scale, and the incidence of adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 88.57% (31 / 35 cases) and 85.71% (30 / 35 cases), respectively. The difference was not statistically significant (P0.05). After treatment, the total scores of BPRS and PSQI were (34.57 鹵2.67), (, 41.95 鹵1.64) and (6.49 鹵0.19), (, 13.05 鹵0.97) in the experimental group and the control group, respectively (P0.05). After treatment, the scores of positive symptoms and negative symptoms were (15.66 鹵1.21), (鹵1.32), (14.84 鹵1.63), () and (15.13 鹵1.10), respectively. The pathological symptoms were (31.37 鹵2.19), (, 31.32 鹵2.19), the total score of PANSS were (66.56 鹵2.34), (, 66.10 鹵2.37), the differences were not statistically significant (P0.05). The main adverse drug reactions in the test group were nausea and vomiting, tachycardia, sit-down and tremor, while the adverse drug reactions in the control group were mainly insomnia, tachycardia, myotonia, sedentary inability, salivation. The incidence of adverse drug reactions in test group and control group was 17.14% and 45.71% respectively, the difference was statistically significant (P0.05). Conclusion the clinical efficacy of quintiapine fumarate combined with aripiprazole in the treatment of schizophrenia is similar to that of aripiprazole alone, but the former can significantly improve the patient's condition and sleep quality, and the safety of the former is higher than that of aripiprazole alone.
【作者單位】： 寧波市強(qiáng)制醫(yī)療所精神科;杭州市第七人民醫(yī)院精神科;
【基金】：浙江省醫(yī)藥衛(wèi)生科技計(jì)劃基金資助項(xiàng)目(2015KYB303)
【分類號】：R749.3
本文編號：2408773
[Abstract]:Objective to observe the efficacy and safety of quintiapine fumarate tablets combined with aripiprazole tablets in the treatment of schizophrenia. Methods 70 patients with schizophrenia were randomly divided into control group (n = 35) and experimental group (n = 35). The control group was given aripiprazole at an initial dose of 5 mg D1), bid, and gradually increased to 2030 mg D1), bid. within 1 week according to the condition of the disease. In the experimental group, aripiprazole was given orally for 10 mg D1), bid, and the initial dose was 100 mg D1), bid,. According to the gradual increase of the disease, the dose of quinolipine fumarate was adjusted to 400 ~ (-1) mg / d ~ (-1), bid; within one week. After one month of treatment, the dosage of quetiapine fumarate was increased to 800 mg D1 according to the specific condition of the patients. The patients in the bid.2 group were treated for 2 months. The clinical efficacy, (BPRS) score of brief psychiatric rating scale, (PANSS) score of Pittsburgh Sleep quality Index (PSQI),) positive and negative symptom scale, and the incidence of adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 88.57% (31 / 35 cases) and 85.71% (30 / 35 cases), respectively. The difference was not statistically significant (P0.05). After treatment, the total scores of BPRS and PSQI were (34.57 鹵2.67), (, 41.95 鹵1.64) and (6.49 鹵0.19), (, 13.05 鹵0.97) in the experimental group and the control group, respectively (P0.05). After treatment, the scores of positive symptoms and negative symptoms were (15.66 鹵1.21), (鹵1.32), (14.84 鹵1.63), () and (15.13 鹵1.10), respectively. The pathological symptoms were (31.37 鹵2.19), (, 31.32 鹵2.19), the total score of PANSS were (66.56 鹵2.34), (, 66.10 鹵2.37), the differences were not statistically significant (P0.05). The main adverse drug reactions in the test group were nausea and vomiting, tachycardia, sit-down and tremor, while the adverse drug reactions in the control group were mainly insomnia, tachycardia, myotonia, sedentary inability, salivation. The incidence of adverse drug reactions in test group and control group was 17.14% and 45.71% respectively, the difference was statistically significant (P0.05). Conclusion the clinical efficacy of quintiapine fumarate combined with aripiprazole in the treatment of schizophrenia is similar to that of aripiprazole alone, but the former can significantly improve the patient's condition and sleep quality, and the safety of the former is higher than that of aripiprazole alone.
【作者單位】： 寧波市強(qiáng)制醫(yī)療所精神科;杭州市第七人民醫(yī)院精神科;
【基金】：浙江省醫(yī)藥衛(wèi)生科技計(jì)劃基金資助項(xiàng)目(2015KYB303)
【分類號】：R749.3
【相似文獻(xiàn)】
相關(guān)期刊論文 前3條
1 張金釗;;加味導(dǎo)痰湯聯(lián)合小劑量富馬酸喹硫平片治療痰濕內(nèi)阻型慢性精神分裂癥36例[J];中醫(yī)研究;2012年07期
2 徐洋;;聯(lián)合用藥治療抑郁伴疼痛的對照研究[J];中國中醫(yī)藥現(xiàn)代遠(yuǎn)程教育;2012年10期
3 ;[J];;年期
，本文編號：2408773
本文鏈接：http://sikaile.net/yixuelunwen/jsb/2408773.html
最近更新
教材專著
